MedTrace Logo

A Phase I Study of RGT-264 in Subjects With Advanced Solid Tumors

NCT05764915 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2024-08-01

No results posted yet for this study

Summary

This is a Phase 1 dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of RGT-264 as monotherapy in subjects with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

RGT-264 phosphate tablets

RGT-264 phosphate tablets will be administered orally once daily (QD).

Sponsors & Collaborators

  • Regor Pharmaceuticals Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-15
Primary Completion
2024-02-20
Completion
2024-02-20

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05764915 on ClinicalTrials.gov